Eisai Co., Ltd. Logo

Eisai Co., Ltd.

A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.

4523 | T

Overview

Corporate Details

ISIN(s):
JP3160400002
LEI:
Country:
Japan
Address:
文京区小石川4丁目6番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Eisai Co., Ltd. is a global, research-based pharmaceutical company founded in 1941. It is engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products, with a portfolio that includes prescription medicines and over-the-counter drugs. The company operates under its core "human health care" (hhc) philosophy, which prioritizes patients and their families to enhance the benefits provided by healthcare. A key corporate initiative involves improving access to medicines for people in developing and emerging countries, exemplified by its program to supply treatments for lymphatic filariasis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 02:50
Registration Form
確認書
Japanese 8.1 KB
2025-11-12 02:48
Interim Report
半期報告書-第114期(2025/04/01-2026/03/31)
Japanese 283.0 KB
2025-08-04 07:00
Major Shareholding Notification
訂正報告書(大量保有報告書・変更報告書)
Japanese 46.9 KB
2025-06-19 09:25
Post-Annual General Meeting Information
臨時報告書
Japanese 31.9 KB
2025-06-13 04:30
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 25.1 KB
2025-06-13 04:29
Registration Form
確認書
Japanese 8.1 KB
2025-06-13 04:28
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 5.2 MB
2025-06-03 08:00
Major Shareholding Notification
変更報告書
Japanese 39.0 KB
2025-05-13 08:00
Major Shareholding Notification
大量保有報告書
Japanese 37.9 KB
2025-05-08 09:00
Regulatory News Service
公開買付報告書
Japanese 41.0 KB
2025-04-01 08:00
M&A Activity
訂正公開買付届出書
Japanese 177.2 KB
2025-03-17 06:00
M&A Activity
公開買付届出書
Japanese 348.4 KB
2025-03-12 07:06
Board/Management Information
臨時報告書
Japanese 21.8 KB
2024-12-11 02:14
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.2 KB
2024-11-15 02:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB

Automate Your Workflow. Get a real-time feed of all Eisai Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eisai Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eisai Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.